Clinical Trials Logo

Filter by:
NCT ID: NCT04844918 Not yet recruiting - Obesity Clinical Trials

A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease

SURMOUNT-J
Start date: May 10, 2021
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to learn more about tirzepatide in participants with obesity disease. The study will also measure how Tirzepatide affects body weight with a low-calorie diet and increased physical activity. The study will last around 72 Weeks.

NCT ID: NCT04844606 Not yet recruiting - Ulcerative Colitis Clinical Trials

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

SHINE-ON
Start date: June 2, 2021
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis or Crohn's disease (CD). The study will last about 172 weeks and may include up to 44 visits.

NCT ID: NCT04838743 Not yet recruiting - Clinical trials for Diabetes Mellitus, Type 2

GOAL: A Research Study Looking at Long Term Blood Sugar Control in People With Type 2 Diabetes Treated With Xultophy® in Local Clinical Practice in Japan.

GOAL
Start date: April 30, 2021
Phase:
Study type: Observational

The purpose of this study is to collect information on how Xultophy® works with other oral anti diabetic medication in patients with type 2 diabetes. Participants will get Xultophy® as prescribed by the study doctor. The study will last for about 26 weeks. Participants will be asked questions about health and diabetes treatment and lab tests as part of normal doctor's appointment.

NCT ID: NCT04828772 Active, not recruiting - COVID-19 Clinical Trials

A Study of Anticoagulation Treatment Patterns and Outcomes of Participants Hospitalized With Coronavirus Disease 2019 (COVID-19) in Japan

Start date: August 17, 2020
Phase:
Study type: Observational

The purpose of this study is to describe demographic and clinical characteristics of participants who are hospitalized due to coronavirus 2019 (COVID-19), treatment use for COVID-19 and COVID-19 symptoms, and composite outcomes of COVID-19. This study will also compare composite outcomes between COVID-19 participants treated with and without anticoagulant therapy during follow-up period.

NCT ID: NCT04826536 Active, not recruiting - Psoriasis Clinical Trials

A Study of Treatment Patterns and Clinical Outcomes of Psoriasis in Japan

Start date: September 17, 2020
Phase:
Study type: Observational

The purpose of this study is to understand current real-world treatment patterns and clinical outcomes, reasons for switching treatment, and participant characteristics using each systemic psoriasis treatment in Japan.

NCT ID: NCT04825860 Recruiting - Schizophrenia Clinical Trials

A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase

Start date: March 29, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

A clinical study to investigate the effect of 2 doses of an investigational drug in acutely psychotic adult patients with schizophrenia. The study will consist of a double-blind phase followed by an open-label extension phase.

NCT ID: NCT04825431 Not yet recruiting - Clinical trials for Healthy Male Subjects

Mass Balance Study of [14C] TAS-205 in Healthy Volunteers

Start date: March 2021
Phase: Phase 1
Study type: Interventional

To evaluate the pharmacokinetics, mass balance recovery, metabolite profile and metabolite identification of [14C]TAS-205 following oral single doses.

NCT ID: NCT04823611 Recruiting - Dyslipidemia Clinical Trials

A Study of AZD8233 in Participants With Dyslipidemia.

HAYATE
Start date: January 20, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase 1 and 2 Study of AZD8233 in Participants with Dyslipidemia and this study consists of Part A and Part B. Part A is designed as a randomized, single-blind (blinding of participants and sites), placebo-controlled, multiple dose, phase 1 study. Part B is designed as a randomized, double-blind, placebo-controlled, dose-ranging, phase 2 study.

NCT ID: NCT04823208 Not yet recruiting - Clinical trials for Diabetes Mellitus, Type 2

A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)

Start date: June 4, 2021
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to learn about the side effects of LY3437943 when given to Japanese participants with type 2 diabetes mellitus. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive injections of LY3437943 or placebo given just under the skin. For each participant, the study will last up to 5 months, inclusive of screening and will include 16 visits to the study center.

NCT ID: NCT04822181 Recruiting - Clinical trials for Non-alcoholic Steatohepatitis

Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

Start date: April 1, 2021
Phase: Phase 3
Study type: Interventional

Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries. Participants will either get semaglutide or a dummy medicine - which treatment participants get is decided by chance. Participants will need to inject themselves with medicine under the skin. Participants will need to do this once a week. The study will last for about 5 years. Participants will have up to 21 clinic visits and up to 9 phone calls with the clinical staff during the study. Some of the clinic visits may be spread over more than one day. Women cannot take part in the study if they are pregnant, breast-feeding or plan to become pregnant during the study period.